Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

eak and trough concentrations as seen with immediate-release guanfacine. INTUNIV is not a controlled substance and does not appear to have a known mechanism for potential abuse or dependence.

Although other ADHD medications work indirectly in the prefrontal cortex, it has been shown that guanfacine, the active ingredient in INTUNIV, works directly by binding selectively to alpha-2A adrenergic cell receptors located in the prefrontal cortex. The prefrontal cortex is an area of the brain associated with executive functioning, ie, working memory, behavioral inhibition, regulation of attention, distractibility, impulsivity, and frustration tolerance. The selective alpha-2A agonist strengthens working memory and prefrontal cortex neuronal firing. This research supports the use of guanfacine for the treatment of ADHD.

Safety data showed that adverse events reported by participants using INTUNIV were generally mild to moderate in severity, with the most common side effects being sedative in nature. Sedation-related, treatment-emergent adverse events were among the most common but emerged in the first two weeks and were usually transient and mild or moderate in severity. Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent) and sedation (13 percent). Small to modest changes in blood pressure, pulse rate, and ECG parameters were observed.

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Approximately 7.8 percent of all school-aged children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of U.S. adults aged 18-44 based on results from the National Comorbidity Survey Replication, a nationally representa
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 The 2009 Frost & Sullivan ... Market is conferred on SonoScape. The award recipient ... need for special features, pricing, and portability - ... The performance of this high-end colour Doppler HCU ... echo ultrasound system. ,, (Logo: ...
(Date:12/14/2009)... 14 Fujirebio Diagnostics Inc., a Malvern-based ... the Year by the Eastern Technology Council at ... in Philadelphia on Thursday, December 3, 2009. ... Philadelphia region,s largest technology and life sciences trade ... Technology and Life Sciences Community, the awards are ...
(Date:12/14/2009)... Texas, Dec. 14 Seven ... with US Oncology Research ... orally at the 2009 San ... Dec. 9-13 at the Henry ... San Antonio, Texas . Fifteen ...
Breaking Medicine Technology:Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 3Fujirebio Diagnostics Named Life Sciences Company of the Year 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2National Institutes of Health award Clemson 249 3 million for tissue regeneration center 10388 1National Institutes of Health award Clemson 249 3 million for tissue regeneration center 10388 2North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 1North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 2North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 3North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 4North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 5North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 6North Shore LIJ Health System Investing 24400M to Connect Up to 7 000 Physicians 13 Hospitals with Electronic Health Records System 59574 7
... Who Responded to, Anti-IL-12/23 ABT-874 after 12 Weeks of Treatment, Maintained Response ... ... AIRES, Argentina, Oct. 1 Results from,an extension to a Phase II ... ABT-874 showed that a,majority of patients who initially responded to treatment maintained ...
... Multi-Center Phase 1 Trial to Commence -, ... Sheets: ARDC), a company focused on the discovery ... viral,diseases, cancer and inflammatory diseases, today announced that ... status to the,Investigational New Drug (IND) application for ...
Other Medicine Technology:Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 2Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 3
(Date:12/15/2009)... Humanic Design, a leading provider of Human Resource Management Systems ... technology solutions from its clients, Self Service Applicant (APSS) to ... HR on strategic matters. , ... ... leading provider of Human Resource Management Systems (HRMS), announced in ...
(Date:12/15/2009)... study finds , , TUESDAY, Dec. 15 (HealthDay News) -- Tight ... with type 2 diabetes who have other medical problems, a ... in type 2 diabetes "has been a subject of controversy ... medicine at the University of California at Irvine, and lead ... the Annals of Internal Medicine . "Our work attempts ...
(Date:12/15/2009)... -- At a time when Americans spend over $50 ... Dr. Raymond Hall is theorizing a painful connection between ... solution called Pillo1 ( www.pillo1.com ) to address the ... St. John,s Medical Plaza Sleep Disorders Center showed that ... sleeping position and promotes increased time spent in REM ...
(Date:12/15/2009)... Staffing Firm to Work For. , ... Alpharetta, GA ... a leading provider of temporary physician and CRNA staffing, as the ... list., , , , ,“We are proud to be recognized on ... in our associates,” said R. Shane Jackson president of LocumTenens.com. “Unquestionably, ...
(Date:12/15/2009)... that certain businesses with large areas where people gather, need ... Fire and rescue personnel agree that for any size business, ... , ... Issaquah, WA (PRWEB) December 15, ... certain businesses with large areas where people gather, need to ...
Breaking Medicine News(10 mins):Health News:Humanic Design is Pleased to Announce Application Self Service (APSS) to its Product Suite to Empower Organizations with Automation 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3Health News:Sleep Study Shows Pillo1 Re-Educates Body to Naturally Move Into Optimal Sleep Position and Increases REM Sleep by 21.3% 2Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3
... of governments of Western Pacific countries in fighting tuberculosis (TB), ... control the disease. ,The region has successfully met ... of TB cases and curing at least 85 percent of ... body's TB programme. ,He was speaking at a ...
... Heart Study, say that if at least one of your parents ... you having lessened the risk factors of heart disease. Yet, ... diet and exercise may well do the trick. , ... Medicine, show that middle-aged children who had at least one parent ...
... suggested that we may not be able to stomach ... frying// pans and baking trays; intake of harmful toxins ... causing health problems, they said. , ... or NICNAS said it is concerned about the use ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
... from mental illness after serving in war-torn Iraq and ... for treatment// from the National Health Service (NHS). ... Ministry of Defence (MoD) showed 2,123 servicemen and women ... from Iraq since 2003. More than 320 soldiers who ...
... set up a facility in Chennai, the state capital, ... ,Called Poison Control Training and Research Centre, it ... can handle emergency situations like mass poisoning. It would ... and counseling. An intensive care unit, a library, a ...
Other Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Take Heart If Your Parents Died at a Ripe Old Age: Framingham Heart Study 2
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Gillies (Converse) Skin Hook, small hook size....
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Medicine Products: